Collaborative Research Using Biosamples from Type 1 Diabetes Clinical Studies (R01 - Clinical Trial Not Allowed) | RFA DK 22 021

Opportunity Information: Apply for RFA DK 22 021

The National Institutes of Health (NIH) released this grant opportunity, RFA-DK-22-021, titled "Collaborative Research Using Biosamples from Type 1 Diabetes Clinical Studies (R01 - Clinical Trial Not Allowed)." It supports R01 research projects focused on understanding the etiology and pathogenesis of type 1 diabetes by making strong use of existing data and biosamples collected during prior clinical trials and clinical studies. The main idea is to get investigators to work in collaborative teams and use these well-characterized human samples and accompanying datasets to answer high-impact mechanistic questions about how type 1 diabetes starts, develops, and progresses, with the longer-term goal of informing better strategies for prevention.

This announcement is specifically oriented toward research that can extract new biological insight from previously collected clinical-study resources rather than launching new interventional trials. Because it is an R01 "Clinical Trial Not Allowed," the proposed work should not include a prospective clinical trial where participants are assigned to an intervention. Instead, projects are expected to be laboratory, translational, computational, or other mechanistic analyses that leverage already-existing trial or study specimens (such as blood-derived materials, serum, plasma, DNA/RNA, immune cells, or other archived biospecimens) along with associated clinical, demographic, immunologic, metabolic, and outcomes data. In practical terms, the FOA is looking for studies that can connect biological signals in those samples to disease mechanisms, including immune dysregulation, beta-cell stress and destruction, genetic and environmental interactions, biomarkers of risk or progression, and pathways that could be targeted to stop or delay disease onset.

A core emphasis of the opportunity is collaboration. NIH is signaling that the strongest applications will likely come from teams that combine complementary expertise, for example immunology, endocrinology, genetics, bioinformatics, systems biology, epidemiology, or biomarker development. The expectation is that collaborative, multidisciplinary approaches will be better suited to tackle complex mechanistic questions and to translate findings into clearer prevention-oriented hypotheses. The research supported under this FOA is intended to clarify disease mechanisms, identify and validate biomarkers, and improve the field's ability to predict risk, stage disease, and design rational prevention strategies grounded in human biology.

The program falls under the NIH assistance listing (CFDA) number 93.847 and is categorized under health-related funding activities. The funding instrument is a grant, and the opportunity category is discretionary. The listed award ceiling is $1,000,000, indicating that budgets can be substantial, consistent with the resource-intensive nature of biosample-based, data-rich analyses. The original closing date in the source information is 2023-10-26, and the FOA was created on 2022-07-11.

Eligibility is broad and includes many organization types across government, academia, nonprofit, and industry. Eligible applicants include state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized; public housing authorities and Indian housing authorities; nonprofits with or without 501(c)(3) status (other than institutions of higher education); for-profit organizations (other than small businesses); and small businesses. In addition, the announcement explicitly highlights a range of other eligible applicants such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, Indian/Native American Tribal Governments other than federally recognized entities, and non-U.S. (foreign) organizations. This breadth signals NIH interest in drawing from diverse research environments and promoting wide participation in type 1 diabetes research.

Overall, this FOA is aimed at accelerating progress in type 1 diabetes prevention by funding mechanistic and biomarker-focused studies that use existing clinical-study biosamples and datasets, performed by collaborative teams capable of generating insights that would be difficult to obtain in smaller, siloed projects.

• The National Institutes of Health in the food and nutrition, health sector is offering a public funding opportunity titled "Collaborative Research Using Biosamples from Type 1 Diabetes Clinical Studies (R01 - Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.847.
• This funding opportunity was created on 2022-07-11.
• Applicants must submit their applications by 2023-10-26. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $1,000,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA DK 22 021

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: